Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 17/20 | 0.79 |
| ▸ | MMP9 | P14780 | 12/20 | 0.79 |
| ▸ | MMP7 | P09237 | 11/20 | 0.79 |
| ▸ | MMP3 | P08254 | 11/20 | 0.79 |
| ▸ | MMP13 | P45452 | 15/20 | 0.70 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.62 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27560678 | 0.92 | MMP1 (0.75) | MMP1MMP9MMP7MMP3MMP13 | |
| SCHEMBL7762105 | 0.91 | MMP1 (0.80) | MMP1MMP9MMP7MMP3MMP13 | |
| SCHEMBL7341460 | 0.91 | MMP1 (0.80) | MMP1MMP9MMP7MMP3MMP13 | |
| SCHEMBL7375954 | 0.90 | MMP1 (0.79) | MMP1MMP9MMP7MMP3MMP13 | |
| SCHEMBL6336332 | 0.90 | MMP1 (0.79) | MMP1MMP9MMP7MMP3MMP13 | |
| SCHEMBL778714 | 0.90 | MMP1 (0.67) | MMP1MMP9MMP7MMP3MMP13 | |
| SCHEMBL6266281 | 0.88 | MMP1 (0.75) | MMP1MMP9MMP7MMP3MMP13 | |
| SCHEMBL7340402 | 0.87 | MMP1 (0.73) | MMP1MMP9MMP7MMP3MMP13 | |
| SCHEMBL6339431 | 0.87 | MMP1 (0.77) | MMP1MMP9MMP7MMP3MMP13 | |
| SCHEMBL6345919 | 0.85 | MMP1 (0.62) | MMP1MMP9MMP7MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849732-B2 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation | AGOURON PHARMACEUTICALS, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1095936-B1 | Intermediates useful for the preparation of metallproteinase inhibitors | AGOURON PHARMA (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20030130506-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation | AGOURON PHARMACEUTICALS, INC. (US) | 2003-07-10 | — | — | US | disclosed |
| US-6500948-B1 | SUCH AS N-HYDROXY-4-(4-((PYRID-4-YL)OXY)BENZENESULFONYL)-2,2-DIMETHYL-TETRAHYDRO-2H -1,4-THIAZINE-3-CARBOXYLIC ACID | AGOURON PHARMACEUTICALS, INC. | 2002-12-31 | — | — | US | disclosed |
| EP-1095936-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation | AGOURON PHARMACEUTICALS, INC. (US) | 2001-05-02 | — | — | EP | disclosed |
| US-6153757-A | A PRODRUG, SALT OR SOLVATE AS ANTITUMOR AGENT AND ENZYME INHIBITOR FOR INHIBITING METALLOPROTEINASES, TUMOR NECROSIS FACTOR | AGOURON PHARMACEUTICALS, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| EP-0874830-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1998-11-04 | — | — | EP | disclosed |
| US-5753653-A | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses | AGOURON PHARMACEUTICALS, INC. (US) | 1998-05-19 | — | — | US | disclosed |
| WO-1997020824-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES, AND METHODS AND INTERMEDIATES USEFUL FOR THEIR PREPARATION | AGOURON PHARMACEUTICALS, INC. (US) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130506-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation | MMP9, MMP3, MMP2 | MMP1 5/4885MMP9 1/4885MMP7 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.